Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091723 · ClinicalTrials.gov registry record · Phase 1
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05091723 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 14 participants.
The verdict
NCT05091723, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
Interventions
- DRUG Nezulcitinib (TD-0903) Dose A
- DRUG Nezulcitinib (TD-0903) Dose B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2021-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05091723
The ClinicalTrials.gov registry entry for NCT05091723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nezulcitinib (TD-0903) Dose A is the first listed.
NCT05091723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05091723 about?
NCT05091723 is a clinical study titled "TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation". This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
What is the current status of trial NCT05091723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-10-13. Estimated completion is 2021-11-24.
What interventions are being tested in trial NCT05091723?
The interventions under investigation include: Nezulcitinib (TD-0903) Dose A (DRUG), Nezulcitinib (TD-0903) Dose B (DRUG).
Who is sponsoring clinical trial NCT05091723?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.